Navigation Links
AstraZeneca submits an sNDA for Symbicort for treatment of asthma in children as young as 6
Date:6/4/2008

Wilmington, DE June 4, 2008 AstraZeneca (NYSE: AZN) today announced that it submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for approval of a new indication for SYMBICORT® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol for the long-term maintenance treatment of asthma in pediatric patients ages 6 to 11 years old. SYMBICORT is currently approved for the long-term maintenance treatment of asthma in patients 12 years and older.

"Millions of children in the U.S. are affected by asthma1," said lead investigator Jeffrey Leflein, MD, Allergy & Immunology Associates of Ann Arbor, Michigan. "SYMBICORT could potentially offer another treatment option for the long-term maintenance of asthma in young children whose condition is not adequately controlled with inhaled corticosteroids alone."

The submission package is based on a robust clinical development program consisting of five active or placebo-controlled Phase III trials assessing the efficacy and safety of SYMBICORT pressurized metered-dose inhaler (pMDI) that included 1,446 children ages 6 to 11 years old with asthma.2 The proposed starting dose for children (80/9 mcg twice-daily) was studied in one pivotal randomized, double-blind, active-controlled, 12-week study that evaluated 256 children ages 6 to 11 years old with mild-to-moderate persistent asthma previously treated with inhaled corticosteroid therapy.3 In this study, SYMBICORT was compared to budesonide pMDI and formoterol dry powder inhaler.3 A second study evaluating this dose included 351 subjects ages 6 to 11 years old.4 Results from both studies demonstrated that SYMBICORT 80/9 mcg twice daily had a similar safety profile to one of the mono-components, budesonide;4,5 likewise, results from the first study also found that SYMBICORT 80/9 mcg twice daily had a similar safety profile to its other mono-component, formoterol.5 The most common adverse events reported wer
'/>"/>

Contact: Katie Neff
katie.neff@astrazeneca.com
302-885-9960
Edelman Public Relations
Source:Eurekalert

Page: 1 2

Related medicine news :

1. FDA Approves AstraZenecas Seroquel(R) for Maintenance Treatment in Bipolar Disorder
2. A Drug That Carries a Lower Risk of Weight Gain Than AstraZenecas Seroquel and Has Antimanic and Antidepressant Effects Would Earn a 30 Percent Patient Share in Bipolar Disorder Treatment
3. Washington University in St. Louis and AstraZeneca Announce Alzheimers Research Collaboration
4. Solcara Helps AstraZeneca Set International Benchmark for Global Media Relations
5. AstraZeneca Gives $1.5 million to Support North Carolina Worksite Wellness Project
6. AstraZeneca - Biologics Day Interviews With Senior Management
7. AstraZeneca Receives Six Months Pediatric Exclusivity Patent Extension for ARIMIDEX(R) (anastrozole) from the FDA
8. AstraZeneca Response to November 2, 2007 Ruling In Re: Pharmaceutical Industry Average Wholesale Price Litigation, MDL No. 1456, U.S. District Court, District of Massachusetts
9. Perrigo Announces that Dexcels Settlement with AstraZeneca Allows OTC Omeprazole Launch Following Final FDA Approval
10. Everett-Area Cancer Patients Can More Easily Navigate Health Care System Thanks to the American Cancer Society and AstraZeneca
11. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... The American Brain Tumor Association is ... Research Fellowships and 2014-2015 Discovery Grant Awards. Through the ... the field with talented, bright young investigators who have ... effects, diagnosis and treatment of brain tumors. This year’s ... the potential to advance the understanding and treatment of ...
(Date:8/27/2014)... to help regulate the blood,s iron supply shows promise as ... results from the first human study of the ... the Journal of the American Society of Hematology ... cells are in short supply or do not function properly. ... enough oxygen, since there are fewer red blood cells to ...
(Date:8/27/2014)... trial participation in the largest ongoing observational study of ... representative of the larger patient base, according to a ... Udell. The study authors call into question the general ... suggest the use of broader enrollment criteria and existing ... that clinical trials can be tremendously expensive and a ...
(Date:8/27/2014)... University,s Center for Leadership in Disability (CLD) has ... and Child Health Bureau of the Health Resources ... Autism Plan for Georgia, aimed at improving services ... , In preparing for this project, CLD worked ... stakeholders from across Georgia. The resulting plan addresses ...
(Date:8/27/2014)... August 27, 2014 Jaha was founded with ... Jaha invested in creating the industry’s most affordable fitness tracker ... that no other apps possess. Jaha plans to ... differentiates in three simple steps: locate, challenge and motivate. ... Aug 26, 2014 to garner support and to raise awareness ...
Breaking Medicine News(10 mins):Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 2Health News:American Brain Tumor Association Awards New Research Grants to Best and Brightest Investigators 3Health News:Drug represents first potential treatment for common anemia 2Health News:Participants of cardiac clinic trials do not represent real world patients, study finds 2Health News:Jaha, Inc. The Most Affordable Fitness Band in the Market Released on Kickstarter 2
... study has shown that children, who are exposed to smoke, ... are likely to have impaired vitamin C levels. Earlier studies ... study, which involved 520 children aged 2 to 12 years, ... have plasma ascorbate concentrations that were lower by an average ...
... the recent past have argued about the implications of Hormone ... menopausal symptoms. A new study, however, has gone further to ... risk of developing breast cancer// if they consumed alcoholic beverages. ... alcohol consumption pattern and on whether they were on HRT ...
... immediately prior to menopause beginning with normal, biological, and ... menstrual periods, is a time of increased vulnerability to ... disorders. Earlier studies have shown that women who experienced ... two to three times more likely to have had ...
... A recent study called 'HERS' conducted by researchers of the ... women, has found that Hormone Replacement Therapy (HRT) may be ... go on to develop diabetes as well. ,The study ... did not or had "impaired fasting glucose" - a ...
... is almost an established truth now. However, many of us ... of pizza could do to our overall health. A recent ... //for Science in the Public Interest (CSPI), which involved 36 ... and looked at dietary information provided by four famous pizza ...
... in the Institute of Preventive Medicine in Copenhagen suggests ... dementia and Alzheimer's disease. Scientists, who found// that people ... two times less likely to develop dementia, said that ... in wine which reduce the occurrence of dementia. This ...
Cached Medicine News:Health News:Women on HRT should avoid alcohol 2Health News:Depressed women show signs of earlier onset of Perimenopause 2Health News:Pizza is bad for health. But, do you know how bad? 2
(Date:8/27/2014)... , Aug. 27, 2014 ... research report is available in its ... for Application and Approval of Imported ... Practices (2014 Edition) ... Now, Chinese regulations on medical ...
(Date:8/27/2014)... BOSTON , Aug. 27, 2014  Columbia Laboratories, ... Company"), a provider of pharmaceutical development, clinical trial manufacturing, ... industry, today announced that it will participate at the ... Investment Conference, to be held in New ... conference at 11:15am on September 9, 2014 at the ...
(Date:8/27/2014)...  UBM Medica US announces that Diagnostic ... imaging professionals, presents special reporting about diagnostic imaging management ... Annual Meeting . Among the materials ... 11 Principles of Successful Labor Management in Radiology : ... , Why Don,t Patients Know the Truth about ...
Breaking Medicine Technology:Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 2Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 3Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 4Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 5Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 6Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 7Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 8Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 9Latest Chinese Guidebook for Application and Approval of Imported Medical Device Registration: From Regulations to Practices (2014 Edition) 10Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 2Diagnostic Imaging Covers Association for Medical Imaging Management (AHRA) 2014 Meeting 3
... Oramed Pharmaceuticals, Inc.,(OTCBB: ORMP.OB) ( http://www.oramed.com ), a ... to present at the 8th National Life,Science & Technology ... by Mr. Nadav Kidron, President and CEO of Oramed,on ... p.m. (local time),at the David Intercontinental Hotel in Tel-Aviv, ...
... Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite ... , COPENHAGEN, June 9 A new analysis ... moderately to severely active rheumatoid arthritis (RA) who ... agents and received subcutaneous injections of SIMPONI(TM) (golimumab) ...
Cached Medicine Technology:Oramed Pharmaceuticals to Present at the 8th National Life Science & Technology Week ILSI -BIOMED Conference, Israel 2009 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 2New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 3New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 4New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 5New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 6New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 7New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 8New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 9New Analysis Shows Efficacy of SIMPONI(TM) (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients 10
... Littmann Electronic Stethoscope Model 4100WS features amplification ... allowing you to reduce ambient noise by ... critical body sounds. Three frequency modes are ... other body sounds: Bell (20-200 Hz), Diaphragm ...
... the best EMR value for many medical ... Charting Plus™ relies heavily on a user-friendly ... improve documentation quality and increase productivity in ... specific to your medical specialty. Each program ...
... is a portable, battery-powered bone growth stimulator used ... device is worn for 30 minutes each day ... fusion site. The device uses a unique technology, ... energy signal that is very potent in its ...
... is a multi-site, implantable biventricular ... and two ventricular ports for ... (AF) who have undergone an ... have NYHA Class II or ...
Medicine Products: